[News Space=Reporter seungwon lee] Yuhan Corporation announced on the 11th that it recorded consolidated operating profit of KRW 104.4 billion in 2025, a 90.2% increase year-on-year. This is the largest operating profit since the company's founding and is significant in that it marks the first time the company has achieved an annual operating profit of KRW 100 billion.

During the same period, sales increased 5.7% year-on-year to KRW 2.1866 trillion, and net income soared 235.9% to KRW 185.3 billion. Yuhan Corporation became the first domestic pharmaceutical company to surpass KRW 2 trillion in annual sales in 2024, and has now achieved sales in the KRW 2 trillion range for two consecutive years. This marks the culmination of profitability-driven growth, with six consecutive years of record sales since 2020 and a surge in net income.

Explosive Growth Analysis by Business Segment

Pharmaceutical business sales increased 3.5% to KRW 1.4009 trillion, solidifying its position as a stable foundation. Overseas business saw rapid growth, reaching KRW 386.6 billion (up 26.1%). This growth was supported by subsidiary Yuhan Chemical's CDM O sales of KRW 289.7 billion (up 36.5%) and exports of KRW 386.5 billion (up 26.1%). However, licensing revenue slightly slowed to KRW 104.1 billion (down 1.1%).

The fourth quarter ended with sales of KRW 546 billion and operating profit of KRW 26 billion, turning a loss from the same period last year into a profit.

Leclaza and Gilead's APIs are powering the performance engine

Key drivers were milestones for the commercialization of the non-small cell lung cancer treatment Leclaza in China and royalties from the FDA approval for its combination with J&J's Librivant (August 2024). The expanded supply of HIV/HCV treatment APIs to Gilead Sciences (a total contract worth KRW 280.8 billion + KRW 85 billion) drove a surge in overseas sales. An improvement in the cost-to-sales ratio and a higher product sales ratio also supported the operating profit expansion.

Declaration of sound management and increased R&D productivity

A Yuhan Corporation official stated his commitment to "strengthening sound management by prioritizing profits and improving R&D productivity." On a separate basis, the company achieved record-breaking performance, with sales of KRW 2.1057 trillion (up 4.8%), operating profit of KRW 110.2 billion (up 57.2%), and net income of KRW 209.6 billion (up 116.7%).